Semaglutide vs Tirzepatide: How They Work in Your Body

Both are weekly injectable medicines that influence appetite and help the body manage glucose. They're often discussed as interchangeable options, but they work through different mechanisms — and understanding that difference explains most of what separates them.

Start with the hormones

Your gut releases hormones after you eat. They're called incretins, and their job is to tell the rest of the body that food has arrived.

GLP-1 (glucagon-like peptide-1) is released from the small intestine. It does several things at once: it prompts the pancreas to release insulin, but only when blood sugar is actually elevated. It suppresses glucagon, the hormone that tells the liver to dump stored glucose into the blood. It slows gastric emptying, so food sits in the stomach longer. And it acts on appetite centers in the hypothalamus, producing the sensation of fullness.

GIP (glucose-dependent insulinotropic polypeptide) is released from the upper small intestine. It also stimulates insulin release in response to glucose, but it has additional roles in fat tissue metabolism and appears to act on appetite through different brain pathways than GLP-1.

Natural incretins break down within minutes. That's the problem both drugs solve.

What semaglutide is

Semaglutide is a synthetic peptide engineered to resemble human GLP-1 closely enough to activate the same receptor — but modified so the body can't clear it quickly. Structural changes protect it from the enzyme that normally degrades GLP-1, and a fatty acid chain lets it bind to albumin in the blood, keeping it in circulation.

The result: a hormone signal that lasts about a week instead of a few minutes. One injection, one pathway, sustained activation.

What tirzepatide is

Tirzepatide is a single peptide that activates two receptors — GLP-1 and GIP. This is unusual. It isn't two drugs combined; it's one molecule engineered to fit both receptor types, built on a GIP-based backbone with modifications that let it also engage GLP-1. It carries the same albumin-binding modification for weekly dosing.

Because it's a dual agonist, it doesn't hit both receptors with equal strength — its activity is weighted more toward GIP. What that imbalance means clinically is still being studied.

Why two pathways might matter

The reasoning behind dual agonism is that GLP-1 and GIP reach the body through partly separate routes. GLP-1 drives fullness and slows digestion. GIP contributes to insulin response and influences how fat tissue handles energy, and may reduce nausea signaling — which is interesting, because nausea is the main limit on how much GLP-1 activity a person can tolerate.

The theory is that engaging both produces effects the single pathway can't reach alone. Clinical trials have generally shown greater average weight reduction with tirzepatide at higher doses, which is consistent with that theory — though averages describe groups, not individuals, and semaglutide has a longer track record and more accumulated long-term data.

What happens in your body, step by step

Neither drug forces weight loss directly. Both change the signals your body uses to regulate intake, and the change in eating follows from that.

Why side effects look the way they do

Nausea, fullness, constipation, and reduced appetite aren't unrelated malfunctions — they're the digestive slowdown working. That's why both drugs start at a low dose and step up gradually: the escalation schedule gives the gut time to adapt to the signal.

Both carry contraindications a prescriber screens for, including a personal or family history of medullary thyroid carcinoma.

A note on compounded versions

Compounded semaglutide and tirzepatide are not FDA-approved products. The FDA has not evaluated them for safety, effectiveness, or quality, and their composition may differ from the approved medicines described here.